# IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: HUMAN PAPILLOMAVIRUSES

## Lyon, 15-22 February 2005

## LIST OF PARTICIPANTS

### Members<sup>1</sup>

- Marc Arbyn, Department of Epidemiology, Scientific Institute of Public Health, Juliette Wytsmanstraat 14, 1050 Brussels, Belgium
- Xavier Bosch, Department of Epidemiology & Cancer Registry, Catalan Institute of Oncology, Avenue Gran Via s/n, km 2.7, 08907 L'Hospitalet del Llobregat, Barcelona, Spain
- Jack Cuzick, Cancer Research UK, Centre for Epidemiology, Mathematics & Statistics, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, EC1M 6BQ, United Kingdom
- Lynette Denny (*unable to attend*), Faculty of Health Sciences, Obstetrics and Gynaecology, Groote Schuur Hospital, Observatory 7925, Cape Town, Western Cape, South Africa
- Denise Galloway, Program in Cancer Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., C1-105, Seattle, WA 98109, USA (*Subgroup Chair, Human Papillomavirus Infection*)
- Anna R. Giuliano, Department of Epidemiology, Risk Assessment, Detection and Intervention Program, H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, MRC 2067D, Tampa, FL 33612, USA
- Rolando Herrero, Costa Rican Institute for Research and Training in Nutrition and Health (INCIENSA), PO Box 125-6151, Costa Rica
- Paul Lambert, McArdle Laboratory for Cancer Research, University of Wisconsin, 1400 University Avenue, Madison, WI 53706, USA (Subgroup Chair, Other Relevant Data)

<sup>&</sup>lt;sup>1</sup> Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

- Herschel Lawson, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Hwy NW, MS K57, Atlanta, GA 30341, USA
- Chris J.L.M. Meijer, Department of Pathology, Vrije Universiteit Medical Center (VUMC), De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
- Joel Palefsky, Department of Medicine, Box 0126, 505 Parnassus Avenue, Room M1203, University of California, San Francisco, San Francisco CA 94143, USA
- Michael Pawlita, Division F020, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany
- You-Lin Qiao, Department of Cancer Epidemiology, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Pan Jia Yuan LN, PO Box 2258, Beijing 100021, China
- Mark Schiffman, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Executive Plaza South, Room 7066, 6120 Executive Boulevard, Rockville, MD 20892, USA (Subgroup Chair, Cancer in Humans)
- Hai-Rim Shin<sup>2</sup>, Division of Cancer Control and Epidemiology, National Cancer Center Research Institute, 809 Madu-dong, Ilsan-gu, Goyang, Gyeong-gi 411-769, Republic of Korea
- Mario Sideri, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy
- Howard D. Strickler, Department of Epidemiology & Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer Building No. 1308, Bronx, NY 10461, USA
- Marjolein van Ballegooijen, Department of Public Health, Faculty of Medicine and Health Sciences, Erasmus University Medical Centre Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
- Luisa Lina Villa, Ludwig Institute for Cancer Research, R. Prof. Antonio Prudente 109-40, 01509-010 Sao Paulo, SP, Brazil
- May Wong, Cancer Etiology Branch (HNCC8), National Cancer Institute, EPN Executive Plaza North, Room 5010, 6130 Executive Boulevard, Rockville, MD 20892, USA
- Harald zur Hausen, German Cancer Research Center, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany (*Meeting Chair*)

#### **Invited Specialists**

M. Saveria Campo<sup>3</sup>, Institute of Comparative Medicine, Department of Veterinary Pathology, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK (*Subgroup Chair, Animal Papillomaviruses*)

<sup>&</sup>lt;sup>2</sup> Current address: Data Analysis and Interpretation Group, WHO-IARC, Lyon

<sup>&</sup>lt;sup>3</sup> Serving as an expert witness for a company with interests in HPV diagnostics or vaccines. On an exceptional basis, served as Chair of the Subgroup on Animal Papillomaviruses. The section on animal papillomaviruses did not contribute to the overall evaluation, because animal papillomaviruses do not infect humans and human papillomaviruses do not infect other animal species.

#### PARTICIPANTS

- Eduardo L. Franco<sup>4</sup> Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montreal, QC, Canada H2W1S6
- Thomas Iftner<sup>5</sup>, Experimental Virology, University of Tübingen, Elfriede Aulhorn Strasse 6, 72076 Tübingen, Germany
- Herbert Pfister<sup>6</sup>, Institute for Virology, University of Köln, Fürst-Pückler-Str. 56, 50935 Köln, Germany

### Representatives

US National Cancer Institute

Jack Gruber, Cancer Etiology Branch, Division of Cancer Biology, National Cancer Institute, Bethesda, MD 20892, USA

## **IARC Secretariat**

Robert A. Baan, Carcinogen Identification and Evaluation (Responsible Officer: Rapporteur. Subgroups on Animal Papillomaviruses and Other Relevant Data) Delphine Boulch, Infections and Cancer Epidemiology Véronique Bouvard, Infections and Cancer Biology Gary Clifford, Infections and Cancer Epidemiology Vincent James Cogliano, Carcinogen Identification and Evaluation (Head of Programme) Min Dai, Infections and Cancer Epidemiology Rajesh Dikshit, Environmental Cancer Epidemiology Carolyn Dresler, Tobacco and Cancer Fatiha El Ghissassi, Carcinogen Identification and Evaluation (Co-rapporteur, Subgroups on Animal Papillomaviruses and Other Relevant Data) Silvia Franceschi, Infections and Cancer Epidemiology Maria Alice Goncalves, Infections and Cancer Epidemiology Yann Grosse, Carcinogen Identification and Evaluation (Rapporteur, Subgroup on Human *Papillomavirus Infection*) Neela Guha, Environmental Cancer Epidemiology Uzma Hasan, Infections and Cancer Biology Charles Hsu, Infections and Cancer Epidemiology Aimee Kreimer, Infections and Cancer Epidemiology Vladimir Krutovskikh, Molecular Carcinogenesis and Biomarkers Jane Mitchell, Carcinogen Identification and Evaluation (Editor) Nikolai Napalkov, Carcinogen Identification and Evaluation

<sup>&</sup>lt;sup>4</sup> Serves as a science advisor for companies that manufacture HPV diagnostic kits or are developing HPV vaccines. Research unit receives support from companies developing HPV vaccines.

<sup>&</sup>lt;sup>5</sup> Serves as a consultant to companies that manufacture HPV diagnostic kits. Research unit receives support from these companies.

<sup>&</sup>lt;sup>6</sup> Serves as a consultant to a company with interests in HPV treatment. Research unit receives support from companies with interests in HPV diagnostics or vaccines.

#### **IARC MONOGRAPHS VOLUME 90**

Sonia Pagliusi Uhe, Initiative for Vaccine Research, WHO Martyn Plummer, Infections and Cancer Epidemiology Béatrice Secretan, Carcinogen Identification and Evaluation (Co-rapporteur, Subgroup on *Cancer in Humans*) Kurt Straif, Carcinogen Identification and Evaluation (Rapporteur, Subgroup on Cancer in Humans) Bakary Sylla, Infections and Cancer Biology Massimo Tommasino, Infections and Cancer Biology Salvatore Vaccarella. Infections and Cancer Epidemiology Administrative assistance

Sandrine Egraz. Carcinogen Identification and Evaluation Michel Javin, Administrative Services Brigitte Kajo, Carcinogen Identification and Evaluation Martine Lézère. Carcinogen Identification and Evaluation Georges Mollon, Communications Elspeth Perez, Carcinogen Identification and Evaluation

NOTE: Minor pertinent interests are not listed. These include consulting on non-regulatory matters totalling less than 2-5% of time and compensation, research grants totalling less than 5-10% of the research budget, occasional travel grants totalling less than 5-10% of time, and stock holdings valued at less than US\$ 10 000 overall.